All competition articles
-
BusinessJ&J’s Intra-Cellular deal could signal more mega-mergers for 2025
£15 billion deal for neuroscience biotech aims to replace revenues from patent expiries
-
BusinessChemicals industry roundup 2024
Europe continues to struggle with high energy and feedstock costs, while US and Asia negotiate supply gluts
-
BusinessExplainer: How is the US pharmaceutical patent system being misused?
What are ‘evergreening’ and ‘thicketing’ and what is being done to reform the system and aid competition?
-
BusinessIllumina to give up Grail as competition appeals fail
Sequencing giant will sell off its former spin-out in accordance with regulator orders
-
BusinessFines upheld for Advanz Pharma over thyroid drug price increases
UK competition tribunal rules liothyronine pricing ’excessive’ and ‘deliberate’
-
BusinessIllumina’s Grail quest results in epic fine
EU and US competition authorities object to firms completing merger without approval
-
BusinessUS trade regulator sues to block Amgen–Horizon merger
Federal Trade Commission has concerns that union will allow Amgen to stifle potential competition for Horizon’s drugs
-
CareersDeveloping entrepreneurship skills for chemistry students
Learning how to turn an idea into commerical success
-
BusinessFragrance firms face coordinated cartel probe
Givaudan, Firmenich, Symrise and IFF raided by competition authorities
-
-
OpinionRewards based on priority drive unnecessary competition
The story of Crispr illustrates how a focus on patents and publications can cause good people to act in unsavoury ways
-
OpinionJumping the vaccine queue
Deals between companies and rich governments offset manufacturing risks, but must not compromise supplies to those in need
-
NewsMerck’s €10k synthesis competition will lab test routes
Pharma company offers €10,000 in prize money for retrosynthesis challenge that will bench test finalists’ proposals
-
BusinessBayer–Monsanto merger momentum
US antitrust regulators approve Bayer’s $66bn takeover of Monsanto, conditional on the company offloading $9bn in assets
-
BusinessUS government urged to exercise drug patent rights
Campaign group says withdrawing Biogen’s license to government patents, or re-licensing them to other companies, could lower MS drug prices
-
BusinessEU investigates Bayer’s Monsanto takeover plan
Commission raises concerns over reduced competition across pesticide and seed markets
-
BusinessEU to investigate Merck KGaA’s merger with Sigma–Aldrich
Commission says Merck failed to disclose a crucial research project
-
BusinessFarmers sue to block Syngenta–ChemChina merger
Planned takeover will decrease competition, leading to higher costs and fewer options for farmers
-
BusinessEU conditionally approves Dow–DuPont merger
To satisfy competition concerns, DuPont will swap crop protection R&D assets for FMC’s nutrition business
-
PromotionJoin us for our science communication competition final
Our 2017 sci-comm competition looks at chemistry where you live